Table 1.
Studies included in this systematic review. Values for age and disease duration are presented as the mean value ± standard deviation, mean value (range) or percentage
| Author, year | Disease | Country | No. of patients | Study type | Subjects mean age in years | Disease duration | Female (%) | Control group for OHRQoL |
|---|---|---|---|---|---|---|---|---|
| Guzeldemir et al. 2009 [17] | HD | Turkey | 47 | monocentric cross-sectional | 46.38 ± 15.10 years | HD: 71.04 ± 1.16 months | 48.9% | no |
| Hajian-Tilaki et al. 2014 [18] | HD | Iran | 145 | monocentric cross-sectional | 58.17 ± 17.76 years | HD: 49.33 ± 46.99 months | 46.9% | no |
| Pakpour et al. 2015 [19] | HD | Iran | 512 | multicentre cross-sectional | 57.7 ± 17.01 | HD: 52.12 ± 29.86 months | 37.1% | yes, healthy control n = 255, 55.8 ± 15.9 years, 38% female |
| Schmalz et al. 2016 [20] | HD, KTx | Germany | HD: 87, KTx: 39 | multicentre cross-sectional | HD: 60.98 ± 14.01 years, KTx: 56.51 ± 11.56 years | n/a | HD: 37.9% KTx: 51.3% | yes, healthy control n = 91, age: 58.31 ± 9.91 years, 65.9% female |
| Lopez-Pintor et al. 2017 [21] | HD | Spain | 50 | monocentric cross-sectional | 66.62 ± 13.96 years | HD: 46.02 ± 44.90 months | 30% | no |
| Lira E Silva et al. 2017 [28] | HD | Brazil | 226 | multicentre cross-sectional | 55.52 ± 14.70 | HD: < 1 year: 17.3%, 1–5 years: 56.6%, > 5 years 26.1% | 40.7% | no |
| Rodakowska et al. 2018 [22] | HD | Poland | 72 | monocentric cross-sectional | 63.2 ± 15.2 years | HD: 43.8 (1–264) months | 60.7% | no |
| Camacho-Alonso et al. 2018 [23] | HD | Spain | 120 | multicentre cross-sectional | 69.90 ± 11.61 years | HD: < 1 year: 11.7%, 1–2.9 years: 10.8%, 3–4.9 years: 22.5%, 5–9.9 years: 35.8%, > 10 years: 19.2% | 31.7% | yes, healthy control n = 120, mean age 67.71 ± 8.96, 37.5% female |
| Schmalz et al. 2018 [24] | HD | Germany | 210 | multicentre cross-sectional | 64.92 ± 15.7 years | HD: 0–2 years: 15.3%, 3–5 years: 18.4%, 6–8 years 17.9%, 9–12 years 15.3%, 13–20 years 17.9%, > 20 years: 15.3% | 35% | no |
| Ruokonen et al. 2019 [25] | KTx | Finland | 51 | prospective follow-up cohort study | 61 (31–86) years | time since KTx 7.1 (1–11) years | 33% | no |
| Kahar et al. 2019 [26] | HD | USA | 70 | multicentre cross-sectional | ≤65 years: 44.1% > 66 years: 55.9% | 4.7 ± 7.5 years | 39.7% | no |
| Oliveira et al. 2019 [27] | HD | Brazil | 180 | multicentre cross-sectional | 51.98 ± 14.34 years | < 12 months: 23.3%, 12–36 months 32.7%, > 36 months | 45% | no |
OHRQoL oral health-related quality of life, n/a not applicable, HD haemodialysis, KTx kidney transplantation